www.fdanews.com/articles/197907-biophytis-to-conduct-phase-23-trial-of-investigational-sarconeos-for-covid-19
![COVID-19](https://www.fdanews.com/ext/resources/test/Drug-Images4/COVID-19-image.gif?t=1615503643&width=430)
Biophytis to Conduct Phase 2/3 Trial of Investigational Sarconeos for COVID-19
July 6, 2020
Biophytis is set to conduct a phase 2/3 trial in the U.S. of its investigational drug Sarconeos for acute respiratory failure associated with COVID-19.
The initial trial will assess the treatment’s safety and efficacy in 50 hospitalized COVID-19 patients. The second phase will evaluate the efficacy of the drug in 300 additional patients.
Biophytis is developing Sarconeos for the treatment of sarcopenia, a skeletal muscle disorder, and Duchenne muscular dystrophy.